2023
Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression
Pakasticali N, Chobrutskiy A, Patel D, Hsiang M, Zaman S, Cios K, Blanck G, Chobrutskiy B. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression. Cancer Informatics 2023, 22: 11769351231177269. PMID: 37313373, PMCID: PMC10259117, DOI: 10.1177/11769351231177269.Peer-Reviewed Original ResearchCancer-testis antigensCancer antigensBreast cancer antigensT cell receptorGranzyme expressionImmune biomarkersCancer immunotherapyPatient outcomesGranzyme BCandidate antigensTestis antigensAdaptive immune receptorsAntigenCDR3 domainsImmune receptorsTumor gene expression dataReceptorsSurvivalAntigen bindingRegion 3Integration of itemsHigh levelsImmunotherapyBreast cancer datasetExpression correlation
2019
An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia
Diviney A, Chobrutskiy BI, Zaman S, Blanck G. An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell International 2019, 19: 73. PMID: 30962767, PMCID: PMC6438000, DOI: 10.1186/s12935-019-0790-5.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaOlder diagnostic ageDiagnostic agePediatric neuroblastomaLymphoblastic leukemiaPrevalent pediatric cancerCancer survival ratesAge of diagnosisYounger patientsSurvival differencesPediatric cancerHigh levelsPatientsNeuroblastomaSurvival rateGene expression markersAgeExpression markersLeukemiaSurvival metricsBiomarker identificationLevelsCancerDiseaseGenes